Call Us Now

+91 9606900005 / 04

For Enquiry

legacyiasacademy@gmail.com

Current Affairs 13 December 2023

CONTENTS EU Proposes Groundbreaking AI Regulation Context: The European Union (EU) is poised to enact the world’s inaugural comprehensive legislation for the regulation of Artificial Intelligence (AI). The proposed framework is anticipated to face a parliamentary vote in early 2024, with potential enforcement as early as 2025. Relevance: GS II: International Relations Dimensions of the […]

PIB Summaries 13 December 2023

CONTENTS AMRIT Technology Context: Recently, the Ministry of Jal Shakti has shed light on the progress of the Jal Jeevan Mission and the Arsenic and Metal Removal by Indian Technology (AMRIT). Relevance: GS III: Science and Technology Dimensions of the Article: AMRIT Technology Overview About Jal Jeevan Mission: Nodal: Ministry of Jal Shakti Implications  Challenges Exercise VINBAX-2023 Context: The Indian Armed […]

NOVEMBER 2023 CURRENT AFFAIRS | MONTHLY COMPILATION | LEGACY IAS ACADEMY

Legacy IAS November 2023 Current Affairs Monthly Compilation includes Editorial Analysis and PIB Summaries which are essential for UPSC Civil Services Exam (IAS Exam) at both the Prelims and Mains levels and the content is segregated in accordance with the subjects in the UPSC Syllabus. Click Here for the November 2023 Monthly Current Affairs Compilation. […]

MONTHLY PIB SUMMARIES NOVEMBER 2023 | MONTHLY COMPILATION FOR UPSC

Legacy IAS November 2023 PIB SUMMARIES – Monthly Compilation for UPSC Civil Services Exam (IAS Exam) will be extremely crucial for your UPSC preparation. The source, Press Information Bureau of India is indubitably the most important source of Current Affairs for any UPSC aspirant. In this Compilation you will find important PIB articles from the […]

Editorials/Opinions Analysis For UPSC 13 December 2023

CONTENTS Gene Therapy for Sickle Cell Disease Context: Less than a month after receiving approval from the UK drug regulator for Casgevy, a gene therapy designed to treat individuals aged 12 and above with sickle cell disease and beta thalassemia, the U.S. FDA has now granted approval for two gene therapies—Casgevy and Lyfgenia—to address sickle […]